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Detecting intratumoral heterogeneity of EGFR activity by
liposome-based in vivo transfection of a ﬂuorescent biosensor
G Weitsman1,13, NJ Mitchell2,12,13, R Evans1, A Cheung1,3, TL Kalber4, R Boﬁnger2, GO Fruhwirth1,11, M Keppler1, ZVF Wright2, PR Barber5,
P Gordon3, T de Koning6, W Wulaningsih7, K Sander8, B Vojnovic5, S Ameer-Beg1, M Lythgoe4, JN Arnold6, E Årstad8, F Festy9,
HC Hailes2, AB Tabor2 and T Ng1,3,10
Despite decades of research in the epidermal growth factor receptor (EGFR) signalling ﬁeld, and many targeted anti-cancer drugs
that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of
overall survival. Intratumoral heterogeneity is proposed as a major mechanism underlying treatment failure of these molecule-
targeted agents. Here we highlight the application of ﬂuorescence lifetime microscopy (FLIM)-based biosensing to demonstrate
intratumoral heterogeneity of EGFR activity. For sensing EGFR activity in cells, we used a genetically encoded CrkII-based biosensor
which undergoes conformational changes upon tyrosine-221 phosphorylation by EGFR. We transfected this biosensor into EGFR-
positive tumour cells using targeted lipopolyplexes bearing EGFR-binding peptides at their surfaces. In a murine model of basal-like
breast cancer, we demonstrated a signiﬁcant degree of intratumoral heterogeneity in EGFR activity, as well as the
pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ. Furthermore, a signiﬁcant correlation between high EGFR
activity in tumour cells and macrophage-tumour cell proximity was found to in part account for the intratumoral heterogeneity in
EGFR activity observed. The same effect of macrophage inﬁltrate on EGFR activation was also seen in a colorectal cancer xenograft.
In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR conformational mutant exhibited
macrophage proximity-independent EGFR activity. Our study validates the use of this methodology to monitor therapeutic
response in terms of EGFR activity. In addition, we found iNOS gene induction in macrophages that are cultured in tumour cell-
conditioned media as well as an iNOS activity-dependent increase in EGFR activity in tumour cells. These ﬁndings point towards an
immune microenvironment-mediated regulation that gives rise to the observed intratumoral heterogeneity of EGFR signalling
activity in tumour cells in vivo.
Oncogene advance online publication, 6 February 2017; doi:10.1038/onc.2016.522
INTRODUCTION
In recent years, there has been a large number of drug failures at
the Phase III and submission stages; particularly with targeted
drugs that have speciﬁc molecular mechanisms of action but have
relatively poor response rates in unselected patient population.1
For example, in breast cancer, the response rates of agents that
target epidermal growth factor receptor (EGFR) vary between
clinical studies, ranging from 6% to 49%, depending on the type
of breast cancer, the stage of the disease and the treatment
used.2–5 To improve these poor response rates, it is essential to
identify companion diagnostic tests that can select patients most
likely to beneﬁt from the drug.6 The companion diagnostic assays
that were based on only EGFR expression per se (as a surrogate
marker of clinical response) are now shown to be inadequate and
insensitive in various tumour types.7 Furthermore, receptor
expression level is not necessarily an indicator of its signalling
activity.
Imaging of EGFR phosphorylation as an indirect surrogate of
EGFR activity has previously been achieved by determination of
FRET efﬁciency via the method of relative donor recovery
following acceptor photobleaching.8 The acceptor photobleach-
ing performed was conﬁned only to regions of interest that
inevitably under-sample the tumour section. EGFR catalytic
activity in cells can alternatively be directly imaged by using a
FRET biosensor known as Picchu (Phosphorylation Indicator of Crk
Chimeric Unit),9 modiﬁed to make it suitable for FRET-FLIM
(Figure 1a). At present these biosensors can only be used to
study murine models where the tumour has been genetically
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engineered to overexpress the biosensor itself.10 In order for the
potential of these biosensors for monitoring the efﬁcacy of drugs
to be realized in a clinical setting, technology to deliver the gene
coding for the biosensor selectively to tumour cells in vivo must be
developed.
Various types of targeted nanoparticles (including liposomes) have
been used successfully to deliver whole body imaging sensors and/or
therapeutic agents into tumours in vivo11 due to the Enhanced
Permeability and Retention effect,12 which is a combination of leaky
tumour endothelium with wide fenestrations, in combination with a
lack of effective lymphatic drainage. The efﬁciency of delivering the
imaging sensors can be further improved by using antibody- or
peptide-based13 approaches to target the liposomes to tumour cells
that have an overexpression of EGFR.14,15
Non-viral gene delivery vectors comprised of cationic lipid/DNA
complexes (lipoplexes) are widely used for the in vitro transfection
of cells, and have considerable therapeutic potential,16 including
systemic gene delivery to tumours.17 However, the low efﬁciency
of gene delivery and poor targeting ability in vivo have limited
their development. Ternary lipid/peptide/DNA (LPD) nanoparticles
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Figure 1. EGF-induced activation of EGFR and phosphorylation of Picchu-X. (a) Schematic representation of conformational changes of the
Picchu-X biosensor upon EGF stimulation and inhibition with TKI enabling FRET measurement of EGFR activity. (b) Effect of Mo-IPQA (10 μM)
on EGF-induced (100 ng/ml) EGFR activation and biosensor phosphorylation in HCC1954 cells. (c) Effect of EGFR knockdown on
phosphorylation of biosensor. (d) FRET/FLIM images of cells treated as in (b). Scale bar is 25 μm. (e) Quantiﬁcation of FRET efﬁciencies for
images in (d). The difference between untreated and EGF-treated cells is statistically signiﬁcant (data are expressed as means± s.e.m.,
*Po0.002, Student’s t-test, N410 images).
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(lipopolyplexes), which include receptor-targeting peptide
sequences, show much higher transfection efﬁciencies.18,19 We
have developed a series of LPD nanoparticles, formulated from
PEGylated lipid components designed to optimize in vivo
nanoparticle stability, and peptide components that optimize
targeting and transfection.18,20–22
Peptides targeting EGFR have been developed, using phage
display or in silico peptide library screening. GE11 (YHWYGYTPQNVI)23
and D4 (LARLLT)24 have been used to prepare EGFR-targeted
liposomes,24 contrast agents25 and polyplexes.26 The targeting
efﬁciency and cellular uptake of these peptides vary depending on
the cell type and the nature of the bioconjugate.25
Here we have achieved for the ﬁrst time targeted lipopolyplex
delivery of an imaging biosensor that can monitor EGFR activity
in situ, in an attempt to provide a more accurate readout of the
sensitivity of tumour cells to EGFR inhibition with tyrosine kinase
inhibitors (TKI) in vivo. This technique, coupled to a phospho-
endogenous protein FLIM,27 shows cell-to-cell heterogeneity in
EGFR activity within a basal-like breast cancer xenograft and a
colorectal cancer model, which can be in part explained by a
signiﬁcant correlation between tumour cell EGFR activity and
macrophage inﬁltration within the tumour microenvironment.
Furthermore, we unraveled a novel mechanism that connects
the proximity of macrophages to tumour cells with the EGFR
signal output and we have shown that macrophages can regulate
oncogenic signalling via iNOS induction. Together, these ﬁndings
point towards an immune microenvironment mediated regulation
that gives rise to intratumoral heterogeneity of EGFR signalling
activity in tumour cells.
RESULTS
Imaging EGFR activity in situ using Picchu-FLIM
To make the EGFR activity biosensor Picchu-X9 compatible with
high-accuracy quantitative FRET-FLIM imaging, we replaced YFP
and CFP with mRFP1 and eGFP. Phosphorylation of the Y221
residue within the biosensor molecule leads to a conformational
change due to interaction between pY221 and the sensor’s SH2
domain (Figure 1a), leading to decreased distance between the
mRFP1 and eGFP resulting in FRET as measured by a decreased
eGFP ﬂuorescence lifetime (tau). Phosphorylation of Y221 in the
Picchu-X sensor was triggered by EGFR activation following EGF
stimulation (Figures 1a and c); the associated increase in FRET
efﬁciency of the biosensor in transfected HCC1954 breast cancer
cells is shown in Figure 1d (shift to ‘warmer’ colours in
pseudocoloured micrographs) and Figure 1e.
The Picchu-X biosensor was further validated by EGFR knock-
down (Figure 1c and Supplementary Figure S9C) and TKI
treatment. We used Mo-IPQA,28 a second-generation version of
PD16839329 that was developed to improve water solubility as a
result of decreased lipophilicity. Mo-IPQA can be radiolabelled
with radio-iodine and used for SPECT imaging in vivo.26 The effect
of EGF on the phosphorylation of the biosensor was abolished by
pre-treatment with Mo-IPQA (Figure 1b). Mo-IPQA at a concentra-
tion of 10 μM was effective for up to 48 h after addition
(Supplementary Figure S9A) and completely abolished the
phosphorylation of EGFR in EGF-stimulated HCC1954 breast
cancer cells (Supplementary Figure S9B), whereas its effect was
limited at a concentration of 20 μM in the MDA-MB-231 breast
cancer cell line. This is likely to be due to a higher level of EGFR
expression in MDA-MB-231 cells or to the cell type-speciﬁc effect
of the inhibitor.28
Design and optimization of EGFR targeting lipopolyplex
complexes
In order to achieve selective delivery and transfection of the plasmid
encoding the Picchu-X biosensor to tumour cells overexpressing
EGFR, we designed lipopolyplexes that would display different EGFR-
targeting peptides23,24 at the surface of the nanoparticle (Figure 2a).
Four bifunctional peptides were synthesized, containing: a linear K16
domain to condense the DNA; the YHWYGYTPQNVI23 (Y-I, I-Y) or
LARLLT24 (L-T, T-L) targeting sequences; and a linker sequence (RVRR)
that will be cleaved after internalization of the nanoparticle by the
endosomal enzyme furin.18,20 For each sequence, one peptide with
the targeting moiety at the C-terminus (Y-I, L-T) and one peptide
with the targeting moiety at the N-terminus (I-Y, T-L) were
synthesized, in order to ascertain which would be most effective to
mediate cell-selective uptake and transfection (Figure 2a). We initially
tested our lipopolyplexes for their ability to deliver DNA to HCC1954
and MDA-MB-231 tumour cells and found the expected plasma
membrane localization of the Picchu-X biosensor (Supplementary
Figure S10B, white arrows), and different from lipid-Cy5 localization
since lipopolyplexes were internalized in order to deliver the Picchu-X
DNA. Although the amount of lipopolyplexes successfully delivered
to MDA-MB-231 cells was ∼ threefold that of non-targeting control
(Cy/UV ratio, Figure 2c) when formulated using the Y-I peptide, the
expression level of Picchu-X was reduced by comparison to non-
targeting control (as monitored by the eGFP/UV ratio, Figure 2d).
These results were replicated in the HCC1954 cells (Figures 3a and b,
Supplementary Figure S10A). The LARLLT and YHWYGYTPQNVI
targeting sequences have been shown to promote uptake of
nanoparticles to tumour cells overexpressing EGFR. In our previous
work22 we have shown that similar LPD formulations have the
targeting moiety of the peptide at the surface of the lipopolyplex. We
have also shown that lipopolyplexes formulated with a non-targeting
K16 peptide, or with a peptide with a randomized targeting sequence,
will have greatly reduced transfection, since the receptor-mediated
uptake pathway will no longer be active.30 Since the Y-I targeting
peptide gave a higher extent of lipopolyplex delivery to the tumour
cells, we further optimized this complex to increase the expression of
Picchu-X.
A decrease of peptide/DNA ratio from 4:1 to 2:1 did not change
the delivery of the complex to the cells (Figure 3c), but signiﬁcantly
increased the expression levels of the biosensor (Figure 3d). This
optimized formulation was thus used in subsequent in vivo
experiments conducted with HCC1954 cells.
Visualizing the distribution and clearance of the TKI Mo-IPQA in
naive mice
Radioiodinated 125I-Mo-IPQA (see SI) was intravenously adminis-
tered to naive (non-tumour bearing) mice. The whole body
distribution of 125I-Mo-IPQA was imaged by SPECT at various time
points to measure its clearance rate over a 24-h time period
(Figure 4a). SPECT/CT images showed that directly after injection
there was uptake in the gallbladder, small intestine and bladder,
suggesting that Mo-IPQA clearance is via the kidneys into the
bladder and the bile duct into the intestines (Figure 4a). I125Mo-
IPQA uptake in the gallbladder increased between 0 and 0.5 h and
was sustained at 1.5 h, but declined at 4 h. In the bladder tracer
uptake remained constant, up to 1 h, indicating that the main
route of excretion was via the bile duct. The 125I-Mo-IPQA activity
within the small intestine moved towards the large intestine at the
later 4-h time point indicating faecal excretion. After 24 h we were
unable to detect any radioactivity by SPECT/CT imaging (data not
shown). These data were aquired by SPECT/CT longitudinally in
the same mice to identify an ideal time point for the quantitative
measurement (% injected dose/gram) of 125I-Mo-IPQA uptake in a
tumour model with gamma counting that is highly sensitive.
Mo-IPQA biodistribution and tumour uptake in the breast cancer
xenograft model
Biodistribution experiments in mice bearing breast cancer xeno-
grafts were performed using carrier-added 125I-Mo-IPQA resulting
in two different doses of morpholino-IPQA (2 μg and 200 μg).
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The results (Figure 4b) conﬁrmed that at 1 h p.i. the predominant
uptake of 125I-Mo-IPQA is within the gallbladder and small
intestine, conﬁrming the results from the SPECT/CT experiment.
There was also some uptake within the kidney suggesting that the
main excretion route is via the bile duct into the small intestines
and ultimately to the faecal matter, with some excretion via the
kidney into the bladder. The tumour uptake of 125I-Mo-IPQA was
similar for both the 2 μg and 200 μg Mo-IPQA doses, which were
doped with 0.5 Mbq (2 ng) I125-Mo-IPQA each. The injected dose/
gram values found were 0.51 ± 0.21 and 0.49%±0.20, respectively
(Figure 4b). Importantly, this translates to an approximate 100-fold
difference in the tumour uptake of total Mo-IPQA in the case of
the administered 200-μg dose (1.209 μg/gram±0.0534) compared
to the 2-μg dose (0.012 μg/gram±0.004; P= 0.023, N= 4, by t-test;
Figure 4c), demonstrating the dose-dependent tumour uptake of
Mo-IPQA.
Measurement of EGFR activity ex vivo
We next assessed the levels of EGFR activity in untreated and
Mo-IPQA-treated tumours ex vivo. We used 30-μm ﬁxed sections of
tumour for two-photon imaging to simultaneously capture the
ﬂuorescence lifetime of eGFP in tumour cells expressing the Picchu-X
biosensor and to measure the distance of the biosensor-expressing
tumour cells to the closest blood vessel and tumour-associated
macrophage (TAM), which were stained with anti-CD31 and F4-80
antibodies, respectively. The ﬂuorescence lifetime of eGFP in the
absence of the mRFP1 acceptor ﬂuorophore (Picchu-X-GFP control
without mRFP1) in cells was 2.06±0.005 ns (N=30 images, from
experiments presented in Figures 1 and 6) and 1.85±0.009 (N=18
images) in tissue (Supplementary Figure S11D). The ﬂuorescence
lifetime of eGFP (Picchu-X biosensor) in untreated tumours was
1.44±0.04 ns (Mean± s.e.m., N=15) suggesting active EGFR in situ,
as observed by donor ﬂuorescence lifetime quenching of the
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Figure 2. EGFR-targeted liposomal delivery system for cell transfection with the Picchu biosensor plasmid. (a) Schematic representation of the
lipopolyplex used for targeted delivery of sensor DNA. The lipopolyplex comprises: pDNA encoding for the Picchu-X sensor; a bifunctional
peptide with a cationic DNA-binding sequence and an EGFR-targeting sequence; a mixture of cationic and neutral lipids (DOPE, DOTMA,
cholesterol and the PEG-shielding lipid DODEG-4); and optionally Cy-5 DOTMA. (b) Structures of key lipid components of the lipopolyplex and
all four sequences of the bifunctional peptides used to formulate lipopolyplexes. Liposomes used in the experiments were formulated
comprising: the helper lipid DOPE (23 mol%), which should fuse with the endosomal membrane and destabilize it;16 the cationic lipid
DODEG4 (20; 39 mol%), which has a short ethylene glycol headgroup to provide steric shielding to the nanocomplex without impeding
cellular uptake; DOTMA (15 mol%); and cholesterol (23 mol%). (c) For in vitro experiments, Cy5-DOTMA (1 mol%) was added to allow detection
of the nanoparticles in cells. Liposome uptake (Cy5/UV ratio represents amount of liposome taken up by all cells (Hoechst staining – UV
channel) in the well) in MDA-MB-231 cells treated with lipopolyplexes modiﬁed with Y-I or L-T peptides (please see Figure 2b for an
explanation of the abbreviations). (d) Quantiﬁcation of the expression of Picchu-X biosensor (eGFP/UV ratio) in the same cells as in
(c) Complexes were prepared at 4:1 peptide/DNA weight ratio. One-way ANOVA to test differences between group means. P values are derived
from a post-hoc Tukey’s test subsequently performed to compare means of individual groups while controlling for family-wise error rate. The
difference was statistically signiﬁcant between control and treatment groups, and data were expressed as means± s.e.m. (*Po0.05,
**Po0.01, Student’s t-test, N= 3).
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Picchu-X biosensor (Figure 5). Interestingly, the activity of EGFR was
heterogeneous (Figure 5a) within the same untreated tumour section
and did not depend on EGFR expression levels (Supplementary
Figures S11A–B). Treatment with Mo-IPQA led to inhibition of EGFR
activity in tumour cells (Supplementary Figure 5b), importantly in a
manner dependent on the administered Mo-IPQA dose (Figure 5c).
EGFR inhibition was demonstrated by a signiﬁcant increase in the
ﬂuorescence lifetime of eGFP from 1.44±0.04 ns (untreated control)
to 1.62±0.04 ns and to 1.77±0.02 ns, respectively, in mice treated
with 2 μg Mo-IPQA and 200 μg Mo-IPQA.
The association between tumour cells and TAMs has been
previously described.31 We analysed the association between
proximity of TAM to tumour cells (dm) and EGFR activity, by
assessing the correlation between dm and Picchu-X biosensor
lifetime, in the presence or absence of in vivo inhibition with
Mo-IPQA. We performed ANCOVA with dm and cell treatment as
predictors of biosensor lifetime to statistically assess how the
proximity of macrophage to tumour cells affects EGFR activity in
the presence or absence of TKI treatment. We found that dm
remained strongly correlated with lifetime irrespective of cell
treatment (P= 0.009), suggesting that Mo-IPQA treatment did
not modify this association. Similar regression slopes (control:
0.0113 ± 0.0032 versus Mo-IPQA: 0.0097 ± 0.0086) linking dm
to lifetime were observed between untreated control and the
Mo-IPQA treated animals (Figure 5d, Supplementary Figure S11C).
Similar statistical analyses did not show a relationship between
EGFR lifetime in biosensor expressing tumour cells and distance to
proximal blood vessels (db, Figure 5e, Supplementary Figure S11C)
suggesting that unlike the proximity to TAMs, the distance of a
given tumour cell to its nearest blood vessel does not signiﬁcantly
inﬂuence EGFR activity. In a colorectal cancer model (LIM1215
xenograft) we observed a signiﬁcant reduction of tumour size
following cetuximab treatment (from 0.16 ± 0.03 cm3 in the
control to 0.04 ± 0.01 cm3 in the cetuximab treatment group,
P= 0.006). An alternative, antibody-based FRET assay for detection
of protein phosphorylation in tissue27 was employed to assess
EGFR activity in LIM1215 xenograft, due to a poor in vivo
transfection efﬁciency. A signiﬁcant cetuximab-associated reduc-
tion of FRET efﬁciency (Supplementary Figure S12B), comparing
untreated control (FRET efﬁciency 4.1 ± 0.006%) and cetuximab-
treated tumour tissues (FRET efﬁciency 0.01 ± 0.003%, Po0.0001),
was found. We also show that EGFR activity measured by Picchu-X
lifetime is consistent with EGFR activity measured by pEGFR-FLIM
assay in cell-based experiment (Supplementary Figure S12A). Due
to a high degree of inﬁltration by macrophages (in clusters) in
LIM1215 xenograft, instead of distance to the nearest macro-
phage, we quantiﬁed the % of area occupied by macrophages in
the ﬁeld of view. We found a signiﬁcant correlation between %
mac and EGFR phosphorylation (Supplementary Figure S12C) in
LIM1215 colorectal tumour xenograft, which further corroborates
our ﬁnding in HCC1954 breast cancer model (Figure 5d). On the
contrary, a non-small cell lung cancer cell line H1975-derived
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Figure 3. Optimization of lipopolyplexes to maximize transfection and expression of Picchu-X biosensor. (a) Transfection efﬁciency of
lipopolyplexes modiﬁed with different targeting peptides in HCC1954 cells (same as in Figure 2c). (b) Expression of Picchu-X biosensor in
the same cells treated in (a). (c, d). Transfection and Picchu-X biosensor expression in HCC1954 cells treated with lipopolyplexes modiﬁed with
Y-I peptide using different peptide/DNA ratios. One-way ANOVA to test differences between group means. P values are derived from a post-
hoc Tukey’s test subsequently performed to compare means of individual groups while controlling for family-wise error rate. The difference
was statistically signiﬁcant between control and treatment groups, and data were expressed as means± s.e.m. (*Po0.01, N= 3).
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xenograft expressing mutant (L858R & T790M double mutation
that renders EGFR constitutively active and resistant to erlotinib/
geﬁtinib32) demonstrated constitutive EGFR activation that is
independent of regulation by the tumour cell:macrophage
proximity (Supplementary Figure S13).
It has been shown that nitric oxide can activate EGFR via
s-nitrosylation.33 We found that pre-treatment of bone marrow-
derived macrophages with conditioned media from HCC1954 cells
led to a 2115 ± 307% transcriptional upregulation of the iNOS
mRNA in macrophages (Figure 6a). This is signiﬁcantly more
pronounced than the known iNOS gene transcriptional response
triggered by inﬂammatory cytokines such as TNFα (Figure 6a).
Co-culture of macrophages with HCC1954 cells resulted in
signiﬁcant activation of EGFR (Figures 6b and c). Addition of the
iNOS inhibitor L-NAME signiﬁcantly decreased the activation of
EGFR in tumour cells co-cultured with macrophages (Figures 6b
and c). These ﬁndings suggest that nitric oxide generation by
activated macrophages can in part explain the dependence of
EGFR activity on tumour cell-macrophage proximity in vivo
(Figure 5d).
Taken together, our data indicate that the proximity of macro-
phages to tumour cells was positively associated with EGFR
activity, and this association persists despite the inhibition of EGFR
activity by a TKI.
DISCUSSION
This study demonstrates intra-tumoral heterogeneity of EGFR
activity in a number of tumour models (breast, colorectal and
lung), using an EGFR-targeted lipopolyplex to deliver DNA
encoding for an EGFR biosensor, in conjunction with ﬂuorescent
lifetime imaging measurements. The EGFR-targeting peptide also
mediates internalization of the lipopolyplex, thus enhancing
transfection of the DNA and expression of the EGFR biosensor.
An ex vivo approach gives proof of principle for the use of an EGFR
biosensor to monitor the pharmacodynamic changes in EGFR
activity in response to targeted therapy. This was coupled to the
tumour tissue pharmacokinetic measurements of a radiolabelled
TKI inhibitor. The mechanistic basis for the intratumoral hetero-
geneity of EGFR activity in this model of breast cancer was
demonstrated to be related to the degree of macrophage
inﬁltration in the tumour microenvironment.
Intravasation is the process whereby tumour cells invade into
tumoral blood vessels and can be considered a rate-limiting step
in the metastatic process. Tumour cells and macrophages are
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Figure 4. Whole body biodistribution and drug tumour uptake of 125I-Mo-IPQA. (a) SPECT/CT images of 125I-Mo-IPQA biodistribution
throughout the whole body of a control mouse. The images show rapid uptake in the gallbladder and bladder suggesting clearance via the
kidney and bile duct into the intestines. (b) % injected dose/gram of all tissues including tumour 1 h after either a 2-μg or 200-μg dose of
Mo-IPQA doped with 0.5 Mbq (2ng) 125I-Mo-IPQA. (c) Total Mo-IPQA (equivalent % injected dose/gram) received by tumour tissue (2 μg and
200 μg). The data show a 100-fold increase in Mo-IPQA concentration within tumour tissue for the 200-μg treated mice compared to the 2 μg.
There was also a small amount of uptake in the thyroid or stomach suggesting that 125I-Mo-IPQA is stable with little degradation of tracer
resulting in free 125I. Tumour uptake studies were undertaken at 1 h post injection (p.i.) due to the observed rapid excretion of 125I-Mo-IPQA
via the gallbladder and kidney in these studies.
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closely associated during intravasation34 and interact through a
paracrine loop involving the macrophage growth factor CSF-1
released from tumour cells, and EGF released by macrophages.35
Measurement of the distance between biosensor-expressing
tumour cells and macrophages in tumour sections showed a
positive correlation between high EGFR activity and proximity to
TAMs. When tumours were treated with Mo-IPQA, the correlation
was maintained. The importance of the CSF-1/EGF paracrine loop
in metastasis has been clearly demonstrated by mammary
xenograft models with a conditional knockout of CSF-1.35
Our study demonstrates for the ﬁrst time that the spatial
relationship between tumour cells and macrophages, which is not
uniform across the tumour bulk, contributes signiﬁcantly towards
the intratumoral, cell-to-cell heterogeneity of EGFR activity.
Recently, there has been a substantial interest in the effect of
TAMs on the efﬁcacy of targeted therapies such as MAPK
inhibitors and sorafenib and so on.36,37 There are no data
available, concerning the effect of pharmacological manipulation
of macrophage function, on the therapeutic efﬁcacy of EGFR TKI.
Here we have found that tumour cell-conditioned media can
upregulate iNOS mRNA transcription in bone marrow-derived
macrophages. Co-culturing macrophages and basal-like breast
cancer cells upregulated the EGFR activity within the tumour cells
as measured by the Picchu-FLIM EGFR sensor. The macrophage-
induced increase in tumour cell EGFR activity can be reduced
signiﬁcantly by an iNOS inhibitor, suggesting a novel mechanism
of how proximity to macrophages in the microenvironment can
regulate tumour cell signalling and hence give rise to the
observed intratumor heterogeneity in EGFR signalling activity.
Although the production of the nitric oxide-derived reactive
nitrogen species peroxynitrite reactive nitrogen by macrophages
has been shown previously to modify chemokines,38–40 the effect
of such nitration effect on macrophage-induced EGFR activity has
not been demonstrated before.
EGFR biosensing was ﬁrst described by the Matsuda group
more than a decade ago.9 However, the preclinical imaging of
EGFR heterogeneity in animal models has been hampered by
difﬁculties in targeting an EGFR biosensor to tumour cells in vivo.
We have addressed this difﬁculty by using a unique liposome-
based delivery system with an EGFR targeting peptide displayed
at the surface of the lipopolyplex, achieving for the ﬁrst time
tumour cell-speciﬁc uptake and expression of the EGFR biosensor
in vivo.
One of the potential problems with EGFR TKI and other targeted
therapies can be the failure for the drug to reach its intended site.
As tumour grows at an accelerated rate, interstitial ﬂuid pressure
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Figure 5. Effect of Mo-IPQA on EGFR activity in HCC1954 xenograft tumours monitored with Picchu-X biosensor. (a) FRET/FLIM images of
Picchu-X biosensor expressed in untreated HCC1954 tumour cells (animal were injected with lipopolyplexes modiﬁed with Y-I peptide and
peptide/DNA in a 2:1 ratio) and lifetime distribution among them. (b) Representative images of Picchu-X biosensor expressing cells from
untreated and treated animals with Mo-IPQA (200-μg dose). (c) Quantiﬁcation of lifetime changes in tumour cells after treatment of animals
with Mo-IPQA at 2-μg and 200-μg doses. Data were expressed as means± s.e.m. (*Po0.005, **Po0.0001, Student’s t-test, tumours from four
animals per group were imaged). (d) The association between proximity of the nearest macrophage to tumour cells and EGFR activity was
evaluated by ANCOVA; in control and high-dose treated groups. (e) The association between proximity of the nearest CD31+ blood vessels to
tumour cells and EGFR activity (P values presented for both ANCOVA models).
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increases. While drugs may ﬂow through the vasculature
surrounding the tumour, the combination of intact vasculature
and high tumour interstitial ﬂuid pressure can result in reduced or
failed drug uptake.41 The importance of interstitial ﬂuid pressure
in vivo has been demonstrated by the use of platelet-derived
growth factor receptor inhibitors that reduce intra-tumoral
hypertension,42,43 which lead to an improved uptake of the
chemotherapeutic agent taxol. Using [125I]-Mo-IPQA we have
shown, by the corresponding reduction on the ﬂuorescence
lifetime of the expressed EGFR biosensor in all regions of interest
when higher doses of TKI were used, that drug delivery is dose-
dependent. Protein activity biosensing and tumour tissue
pharmacokinetic measurements, afforded by quantifying the
tumour uptake of a radiolabelled inhibitor, can therefore be
coupled to interstitial ﬂuid pressure measurements to fully
understand the heterogeneity of treatment response among
different tumour loci within the same animal as we recently
reported using sodium iodide symporter SPECT imaging.44 In
other cancer types such as metastatic colorectal tumours, only 10–
20% of patients with wild type KRas/BRAF respond to anti-EGFR
monotherapy using monoclonal antibody therapies (for example
Cetuximab against EGFR45). Factors besides tissue pharmacoki-
netics, such as between-patient heterogeneity in FcγR-dependent
innate immune function as well as target receptor availability
(which may be independent of the RTK activity), are likely to also
have an important inﬂuence on the efﬁcacy of EGFR antibody
treatment.46
The heterogeneity of signalling activity between individual cell
populations within a tumour, which persists in the presence
of treatment (in this case an EGFR TKI, Figure 5d), may culminate
in a potentially treatment-resistant cell subpopulation and may
therefore provide an explanation for therapeutic failures.47 Further
investigation of the observed macrophage proximity-dependent
heterogeneity of EGFR activity between tumour cell subpopulations,
will therefore guide the development of future strategies that may
combine molecule-targeted cancer therapy with immunomodulatory
agents (for example against TAM, which may have been shown to
have tumour promoting function in breast and other tumour
types48).
MATERIALS AND METHODS
Tissue culture, reagents and antibodies
Basal-like breast cancer cell-lines, MDA-MB-231 (purchased from ATCC) and
HCC1954 (generous gift of Dr Andrew Tutt, King’s College London, UK),
independently validated by STR DNA ﬁngerprinting at The Institute of
Cancer Research (London, UK), were maintained in DMEM and RPMI-1640,
respectively (Life Technologies Ltd, Paisley, Uk) and tested to be
mycoplasma free. Bone marrow macrophages were extracted from
HCC1954 tumour bearing mice, cultured with macrophage colony
stimulating factor-1 (GFM8-100, Cambridge Bioscience, UK) for 7 days
before use in experiments. Antibodies: anti-EGFR (clone D38B1), anti-p-
Y1173-EGFR (clone 53A5), anti-p-Y221-CRKII (#3491) and CRKII (#3492)
were from Cell Signalling (Danvers, MA, USA); anti-CD31 (clone 2H8) from
AbD Serotec Ltd (Oxford, UK); Anti-F4/80 (clone A3-1) from Abcam
(Cambridge, UK). Goat anti-rat-Alexa647 (415-605-166-JIR) and goat anti-
hamster-Cy3 (307-165-003-JIR) were from Stratech Scientiﬁc, UK. 1,2-Dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE) was from Avanti Polar Lipids Inc.
(Alabaster, AL, USA) and Cy5-NHS was from GE Healthcare (Amersham, UK).
Cholesterol and all general reagents for chemical synthesis were from Sigma-
Aldrich (Dorset, UK). N-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)-N,N-
dimethyl-2,3-bis((Z)-octadec-9-enyloxy)propan-1-aminium (DODEG4)49 and N,
N,N-trimethyl-2,3-bis((Z)-octadec-9-enyloxy)propan-1-aminium (DOTMA)50,51
were synthesized as previously described. EGFR TKI PD168393 was from
Santa Cruz Biotech (Heidelberg, Germany).
General methods for chemical synthesis are included in the Supporting
Information. The EGFR inhibitor (E)-but-2-enedioic acid [4-(3-iodoanilino)-
quinazolin-6-yl]-amide-(3-morpholin-4-yl-propyl)-amide (Mo-IPQA) was
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Figure 6. Effect of nitric oxide inhibitor on EGFR activity in HCC1954 cells co-cultured with activated macrophages. (a) mRNA level of iNOS was
detected by qPCR (relative to the house keeping gene Tata-binding protein) in mouse macrophages treated with mouse tumour necrosis
factor alpha (50 ng/ml) or conditioned media of HCC1954 cells for 3 days. One-way ANOVA to test differences between group means. P values
are derived from a post-hoc Tukey’s test subsequently performed to compare means of individual groups while controlling for family-wise
error rate. The difference was statistically signiﬁcant between control and treatment groups, data were expressed as means± s.e.m.
(*Po0.005, N= 3). (b) HCC1954 cells expressing Picchu-X biosensor were co-cultured with activated macrophages from (a) for 48 h. Treated
with L-NAME (2 mM) for 1 h, ﬁxed and imaged. Presence of macrophages signiﬁcantly increased FRET efﬁciency (**Po0.0001, N= 6), which
was signiﬁcantly decreased by iNOS inhibitor (*P= 0.01). (c) FRET/FLIM images of cells with and without L-NAME; and with and without
activated macrophages. Scale bar is 25 μm.
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synthesized28 and its HPLC and 1H NMR characterization data were
identical to the literature (Supplementary Supporting Figure S0). Synthesis
of morpholino-[125I]-IPQA was carried out as previously described.28,52 Cy-5
DOTMA was synthesized from a previously described intermediate51 in two
steps (Supplementary Supporting Information). The four bifunctional
peptides used in this study (Figure 2) were synthesized using standard
solid-phase peptide synthesis techniques and puriﬁed by HPLC. Purity and
identity of the peptides were assessed by analytical HPLC and electrospray
mass spectrometry (Supplementary Supporting Figures S1–S8).
Preparation and characterization of liposomes
All lipid components were dissolved in CHCl3 to a concentration of 1 mM.
The lipid quantities were mixed together in the following molar ratios:
DODEG4 39 mol%; DOPE 23 mol%; DOTMA 15 mol%; cholesterol 23 mol%.
The solvent was then removed under reduced pressure to form a thin ﬁlm,
which was further dried on a high vacuum line for 2 h. This was hydrated
with sterilized water to the desired total lipid concentration, sonicated for
10 min, and used immediately. Methods for the characterization of the
liposomes are described in the Supplementary Supporting Information,
and the DLS and zeta potentials are given in Supplementary Table S1.
Lipopolyplexes used for in vitro experiments were formulated as
described (including Cy5-DOTMA) at a total lipid-cholesterol concentration
of 130 μM using a bath sonicator. For every 100 μL of sonicated liposome
solution, 4–16 μg of peptide was added followed by 1–4 μg of plasmid
DNA coding for the Picchu-X sensor. The samples were mixed and used
immediately.
The lipopolyplexes used for the in vivo studies were prepared as
described (without the inclusion of the Cy5-DOTMA) at a total lipid
concentration of 1.95 mM using a probe sonicator (Soniﬁer SLPe, Branson,
USA; 10 min continuous pulse). Two equivalents of peptide Y-I (1–5 mM
solution made from stock in distilled water—w/w relative to the DNA
sensor) were added to the liposome solution (usually 136 μg per mouse to
give a 2:1 ratio). This solution was then diluted to an overall lipid
concentration of 0.5 mM using sterilized water. The desired amount of DNA
(68 μg per mouse) was then separately diluted to a concentration of
0.2 μg/μl and added to the liposome solution. The sample was allowed to
sit for 10 min after gentle mixing. The sample was then concentrated to an
appropriate volume (1.95 mM total lipid concentration) to allow injection
into the mouse models (100 μl per mouse) using VivaSpin columns
(Molecular Weight Cut Off 10 000, GE Healthcare Life Science Ltd,
Amersham, UK).
In vitro liposomal transfection
13 μM liposome solution, containing 0.4 μg of sensor plasmid DNA and
1.6 μg of peptide per 100 μl, was applied to cells at 60% conﬂuence in
six-well-plates. Following 4 h incubation at 37 °C, cells were washed twice
with sterile PBS to remove unbound liposomes and incubated with normal
growth medium for 48 h to allow protein expression. All in vitro
experiments were repeated at least three times.
In vivo experimentation
Subcutaneous xenograft animal models of cancer (H1954 cells for breast,
H1975 cells for lung and LIM1215 cells for colorectal in Charles River female
CD1-Foxn1 nu/nu mice (6–8 weeks old)) were used in this study. The
objective was to investigate the effect of EGFR-speciﬁc TKI on EGFR activity
in situ using an intravenously administered liposome-encapsulated EGFR
biosensor. All animal studies were approved by the University College
London and King’s College London Biological Services Ethical Review
Committee and licensed under the UK Home Ofﬁce regulations (PPL no:
70/7350) and the Animals (Scientiﬁc Procedures) Act 1986 (Home Ofﬁce,
London, United Kingdom), informed by the National Cancer Research
Institute Guidelines.53 Animal weights and tumour volumes were recorded
every 2 days. Cohort sizes of at least four mice per treatment group were
used (according to previously published method54). All mice used for
experiments were female and randomly assigned to non-blinded
treatment groups. Experiments were performed in at least duplicate.
Treatment with clinical-grade cetuximab (Erbitux, Merck, Feltham, UK) was
20 mg/kg IP biweekly for 2 weeks.
Single-photon emission computed tomography (SPECT)/CT
imaging of Mo–IPQA clearance in control mice
Two mice (6–8 weeks old) were anaesthetized with an isoﬂurane/O2 mix
and a tail vein cannulated for the delivery of approximately 7 MBq of 125I-
Mo-IPQA (equates to 28 ng) in 300 μl sterile saline.
Tumour induction, in vivo lipopolyplex transfection, whole body
Mo-IPQA biodistribution and tumour uptake
Mice were injected subcutaneously on the right ﬂank with 3 × 106
HCC1954 cells in 100 μl serum-free media. Tumours were measured using
a calliper. Tumour volumes were estimated assuming an ellipsoid shape
using the formula volume= length×width× depth×π/6. Once tumours
reached approximately 200 mm3, 100 μl of a1.95 μM lipopolyplex solution
containing 136 μg of peptide and 68 μg Picchu-X (or Picchu-X-GFP control)
DNA were injected i.v. into the tail vein. After 48 h mice received i/v
injection of saline with 2 μg Mo-IPQA or 200 μg Mo-IPQA. Both the 2 μg
and 200 μg doses contained 2 ng of 125I-Mo-IPQA with a dose of 0.5 MBq/
mouse. After 1 h, the mice were exsanguinated by cardiac puncture and
culled via a schedule 1 method. Various organs were harvested from each
animal, weighed and gamma counted (PerkinElmer, Coventry, UK).
The tumours were then frozen in OCT for histology.
Microscopy
Confocal ﬂuorescence images were acquired on a confocal ﬂuorescence
laser-scanning microscope (model LSM 510; Carl Zeiss Inc., Cambridge, UK)
equipped with a × 63/1.4NA Plan-APOCHROMAT oil immersion objective.
Fluorescence Lifetime images of Picchu-X-transfected cells in cell culture or
tissue sections from mouse xenografts were captured on a multiphoton
microscope, and analysed as previously described.55,56
Statistical analyses
Student’s t-test was employed to assess changes in biosensor lifetime
following treatment with Mo-IPQA. The distances between biosensor-
expressing tumour cells and nearby macrophage (dm) and as well as blood
vessels (db) biosensor-expressing tumour cells (d) were assessed in relation
to biosensor lifetime by simple linear regression in all imaged cells (n= 29).
For any signiﬁcant association, analysis was repeated, in each cell group
separately (control, Mo-IPQA-treated). Regression coefﬁcients or slopes in
the control and Mo-IPQA-treated group were further compared through a
test for interaction by incorporating a product of dm or db and cell
treatment in the regression model. The association between dm or db, cell
treatment and lifetime was further assessed using analysis of covariance
(ANCOVA), with dm or db and cell treatment as predictors of lifetime.
Statistical signiﬁcance was set at Po0.05. The above analyses were
performed with R version 3.1.1 (R Foundation for Statistical Computing).
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